Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LRAT | O95237 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FGF1 | P05230 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718576 | 1.00 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL16589514 | 1.00 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL11941427 | 1.00 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL13488460 | 1.00 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14339510 | 0.93 | MEN1 (0.45) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL13485608 | 0.93 | MEN1 (0.45) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL13990757 | 0.90 | MEN1 (0.49) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14639596 | 0.90 | MEN1 (0.49) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL13903853 | 0.90 | MEN1 (0.49) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL17816417 | 0.90 | MEN1 (0.49) | MEN1LRATTRPV1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189573-A1 | NOVEL HEMOSTATIC PATCH AND USES THEREOF | RUBIN LEO (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170049710-A1 | NOVEL FORMULATIONS AND METHODS | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES, LLC (US) | 2017-02-23 | — | — | US | disclosed |
| US-9414967-B2 | Composition, preparation, and use of chitosan shards for biomedical applications | LOMA LINDA UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9381255-B2 | Formulations comprising T3 nanoparticles | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9364578-B2 | Hemostatic agent for topical and internal use | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160151532-A1 | NOVEL HEMOSTATIC PATCH AND USES THEREOF | RUBIN LEO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160121021-A1 | COMPOSITION, PREPARATION, AND USE OF CHITOSAN SHARDS FOR BIOMEDICAL APPLICATIONS | UNIV LOMA LINDA (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160082037-A1 | COMPOSITION, PREPARATION, AND USE OF CHITOSAN POWDER FOR BIOMEDICAL APPLICATIONS | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2016-03-24 | — | — | US | disclosed |
| US-20160058904-A1 | CHITOSAN-BASED HEMOSTATIC TEXTILE | NORTH CAROLINA STATE UNIVERSITY | 2016-03-03 | — | — | US | disclosed |
| US-9259357-B2 | Composition, preparation, and use of chitosan shards for biomedical applications | LOMA LINDA UNIVERSITY (US) | 2016-02-16 | — | — | US | disclosed |
| US-8404281-B2 | Formulations | AVANT GARDE THERAPEUTICS & TECHNOLOGIES LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120093686-A1 | CHITOSAN-BASED HEMOSTATIC TEXTILE | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2012-04-19 | — | — | US | disclosed |
| US-8153612-B2 | Injectable chitosan mixtures forming hydrogels | CHI2GEL LTD. (IL) | 2012-04-10 | — | — | US | disclosed |
| US-20120059410-A1 | WOUND CLOSURE DEVICE AND METHOD | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110142947-A1 | NOVEL FORMULATIONS | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC | 2011-06-16 | — | — | US | disclosed |
| US-20100173228-A1 | Nanotube and Carbon Layer Nanostructured Composites | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-08 | — | — | US | disclosed |
| US-20100068461-A1 | NANOSTRUCTURED COMPOSITES | UNIVERSITY OF WOLLONGONG (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100048508-A1 | MIXTURE AND METHOD FOR REDUCING CHOLESTEROL USING HYDROPHOBIC MICROPARTICLES | BEN-BAR TECHNOLOGY 2006 LTD. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100023101-A1 | BIOCOMPATIBLE COMPOSITES | UNIVERSITY OF WOLLONGONG (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20090004276-A1 | Novel injectable chitosan mixtures forming hydrogels | MOR RESEARCH APPLICATIONS LTD. (IL) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100023101-A1 | BIOCOMPATIBLE COMPOSITES | F12, MATR3, FIBP | MEN1 282/4885LRAT 4247/4885TRPV1 4549/4885 |
| US-20160082037-A1 | COMPOSITION, PREPARATION, AND USE OF CHITOSAN POWDER FOR BIOMEDICAL APPLICATIONS | CHIT1, NCDN, CHIA | MEN1 294/4885LRAT 4842/4885TRPV1 4014/4885 |
| US-20170049710-A1 | NOVEL FORMULATIONS AND METHODS | VIPR1, VIPR2, VIP | MEN1 528/4885LRAT 2030/4885TRPV1 745/4885 |
| US-20100048508-A1 | MIXTURE AND METHOD FOR REDUCING CHOLESTEROL USING HYDROPHOBIC MICROPARTICLES | CETP, LIPA, CHMP4B | MEN1 857/4885LRAT 17/4885TRPV1 4092/4885 |
| US-20110142947-A1 | NOVEL FORMULATIONS | TNNI3, TNNT2, TNNC1 | MEN1 1818/4885LRAT 813/4885TRPV1 606/4885 |
| US-20090004276-A1 | Novel injectable chitosan mixtures forming hydrogels | HDAC3, EP300, CHIA | MEN1 2485/4885LRAT 3371/4885TRPV1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.